Assessment and care of substance use disorder within mental health services are essential due to the high prevalence and harms associated with comorbidity. Substance use disorder assessment and care are routinely recommended in clinical guidelines; however, processes are not agreed. This systematic review of routine clinical practice in relation to substance use disorders in adult mental health service aims to identify routine assessment and diagnosis processes, the proportion of patients and service episodes in which they occur and their outputs.
Methods:
We searched MEDLINE, PsycINFO, Embase and relevant Cochrane databases for articles until July 2024 reporting on substance use assessment, diagnosis or treatment in adults receiving routine mental health service and locating additional articles by snowballing. Variables including setting, study method, period, cohort, substances, clinical assessment type, diagnosis and care pathways were compared.
Results:
In 137 heterogeneous studies reporting routine practice within a wide variety of adult mental health service from 29 nations, 44 (32%) expected or reported on substance use assessment in domains of pattern or impact. However, 23 studies (17%) reported structured approaches to substance use disorder assessment, while 67 (49%) reported a diagnostic structure, including classification system. Diagnostic prevalence varied markedly. Treatment was reported in 16 studies (12%) and no substance use disorder outcomes were reported.
Conclusion:
This systematic review shows marked variation in routine practice in mental health service across a range of substance use disorder assessment and diagnosis processes. To better identify substance use disorder, enhance its care and reduce associated morbidity, adult mental health service may benefit from standardising expectations and systematically monitoring the performance of substance use assessment and diagnosis.
ACSQHC (ed.) (2020) Implementing the Comprehensive Care Standard: Clinical Assessment and Diagnosis. Sydney, NSW, Australia: Australian Commission on Safety and Quality in Health Care.
2.
AddingtonDAbidiSGarcia-OrtegaI, et al. (2017) Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders. Canadian Journal of Psychiatry62: 594–603.
3.
AkosileWMcDermottBM (2015) Use of the urine drug screen in psychiatry emergency service. Australasian Psychiatry23: 128–131.
4.
AnanthJVandewaterSKamalM, et al. (1989) Missed diagnosis of substance abuse in psychiatric patients. Hospital & Community Psychiatry40: 297–299.
5.
AnicARobertsonLJ (2020) Prevalence and clinical correlates of substance use amongst acute psychiatric inpatients in Gauteng, South Africa. The South African Journal of Psychiatry26: 1526–1528.
6.
APA (2016) Practice Guidelines for the Psychiatric Evaluation of Adults (ed. APA), 3rd Edition.Arlington, VA: American Psychiatric Association.
7.
APA (2021) Practice Guideline for the Treatment of Patients With Schizophrenia, 3rd Edition.Washington, DC: American Psychiatric Association.
8.
APA (2022) Diagnostic and Statistical Manual of Mental Disorders (Text Revision), 5th Edition.Washington, DC: American Psychiatric Association.
9.
ArseneaultLCannonMWittonJ, et al. (2004) Causal association between cannabis and psychosis: Examination of the evidence. The British Journal of Psychiatry184: 110–117.
10.
AwanSSamokhvalovAVAleemN, et al. (2015) Development and implementation of an ambulatory integrated care pathway for major depressive disorder and alcohol dependence. Psychiatric Services66: 1265–1267.
11.
BahorikANewhillCQueenC, et al. (2014) Under-reporting of drug use among individuals with schizophrenia: Prevalence and predictors. Psychological Medicine44: 61–69.
12.
BakerALewinTReichlerH, et al. (2002) Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction97: 1329–1337.
13.
BakerFMHaningWF3rd (2001) Substance abuse and dependence in a public hospital: Hawaii. Hawaii Medical Journal60: 35–38.
14.
BarnabyBDrummondCMccloudA, et al. (2003) Substance misuse in psychiatric inpatients: Comparison of a screening questionnaire survey with case notes. BMJ: British Medical Journal327: 783–784.
15.
BarnesTRDrakeRPatonC, et al. (2020) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology34: 3–78.
16.
BarnettKMercerSWNorburyM, et al. (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. The Lancet380: 37–43.
17.
BellJKilicCPrabakaranR, et al. (2013) Use of electronic health records in identifying drug and alcohol misuse among psychiatric in-patients. Psychiatrist37: 15–20.
18.
BlondeLKhuntiKHarrisSB, et al. (2018) Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy35: 1763–1774.
19.
CacciolaJSAltermanAIDephilippisD, et al. (2013) Development and initial evaluation of the Brief Addiction Monitor (BAM). Journal of Substance Abuse Treatment44: 256–263.
20.
CareyKBCorreiaCJ (1998) Severe mental illness and addictions: Assessment considerations.(Severe Mental Illness and Comorbidity). Addictive Behaviors23: 735–748.
21.
CatonCLSametSHasinDS (2000) When acute-stage psychosis and substance use co-occur: Differentiating substance-induced and primary psychotic disorders. Journal of Psychiatric Practice6: 256–266.
22.
ChanYFHuangHSieuN, et al. (2013) Substance screening and referral for substance abuse treatment in an integrated mental health care program. Psychiatric Services64: 88–90.
23.
Clay-WilliamsRBraithwaiteJ (2016) Realigning work-as-imagined and work-as-done: Can training help? In: BraithwaiteJWearsRLHollnagelE (eds) Resilient Health Care, Volume 3: Reconciling Work-As-Imagined and Work-As-Done, 1st Edition. London: CRC Press, pp. 153–162.
24.
CocchiACeratiGLoraA, et al. (2014) Patients with first-episode psychosis are not a homogeneous population: Implications for treatment. Clinical Practice and Epidemiology in Mental Health10: 1–8.
25.
ConusPCottonSSchimmelmannBG, et al. (2007) The first-episode psychosis outcome study: Premorbid and baseline characteristics of an epidemiological cohort of 661 first-episode psychosis patients. Early Intervention in Psychiatry1: 191–200.
26.
CrockfordDAddingtonD (2017) Canadian schizophrenia guidelines: Schizophrenia and other psychotic disorders with coexisting substance use disorders. Canadian Journal of Psychiatry62: 624–634.
27.
DamsGMKetchenBRBurdenJL, et al. (2024) Effectiveness of residential treatment services for veterans with substance use disorders: A propensity score matching evaluation. Drug and Alcohol Dependence255: 1–8.
28.
DarkeSHallWWodakA, et al. (1992) Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: The Opiate Treatment Index. British Journal of Addiction87: 733–742.
29.
DeadyMTeessonMMillsK, et al. (2013) One Person, Diverse Needs: Living With Mental Health and Alcohol and Drug Difficulties. Sydney, NSW, Australia: National Mental Health Commission.
30.
DennisMLChanYFFunkRR (2006) Development and validation of the Gain Short Screener (GSS) for internalizing, externalizing and substance use disorders and crime/violence problems among adolescents and adults. The American Journal on Addictions15: 80–91.
31.
DowlingNACowlishawSJacksonAC, et al. (2015) Prevalence of psychiatric co-morbidity in treatment-seeking problem gamblers: A systematic review and meta-analysis. Australian and New Zealand Journal of Psychiatry49: 519–539.
32.
DrakeREEssockSMShanerA, et al. (2001) Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services52: 469–476.
33.
DVA (2021) VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Washington, DC: Department of Veterans Affairs & Department of Defense.
34.
EndicottJSpitzerRL (1978) A diagnostic interview: The schedule for affective disorders and schizophrenia. Archives Of General Psychiatry35: 837–844.
35.
Fals-StewartWO’FarrellTJFreitasTT, et al. (2000) The Timeline Followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties. Journal of Consulting and Clinical Psychology68: 134–144.
36.
FennigSNaisberg-FennigSCraigTJ, et al. (1996) Comparison of clinical and research diagnoses of substance use disorders in a first-admission psychotic sample. American Journal on Addictions5: 40–48.
37.
FirstMBGaebelWMajM, et al. (2021) An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry20: 34–51.
38.
GalletlyCCastleDDarkF, et al. (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry50: 410–472.
39.
GalletlyCAFieldCDPriorM (1993) Urine drug screening of patients admitted to a state psychiatric hospital. Hospital & Community Psychiatry44: 587–589.
40.
GhitzaUEGore-LangtonRELindbladR, et al. (2013) Common data elements for substance use disorders in electronic health records: The NIDA Clinical Trials Network experience. Addiction108: 3–8.
41.
GoodrichDMiake-LyeIBraganzaMzWawrinN, et al. (2020) Quality Enhancement Research Initiative. QUERI Roadmap for Implementation and Quality Improvement (ed. U. S. Department of Veterans Affairs). Washington, DC: Veterans Health Administration Office of Research and Development Health Services Research and Development.
42.
GordonAJDrexlerKHawkinsEJ, et al. (2020) Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within veteran health affairs’ facilities. Substance Abuse41: 275–282.
43.
GothamHJBrownJLComatyJE, et al. (2013) Assessing the co-occurring capability of mental health treatment programs: The Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) index. The Journal of Behavioral Health Services & Research40: 234–241.
44.
GummattiraPCowanKAAverillKA, et al. (2010) A comparison between patients diagnosed with bipolar disorder with versus without comorbid substance abuse. Addictive Disorders & Their Treatment9: 53–63.
45.
HansenSSMunk-JørgensenPGuldbaekB, et al. (2000) Psychoactive substance use diagnoses among psychiatric in-patients. Acta Psychiatrica Scandinavica102: 432–438.
46.
HelzerJEClaytonPJPambakianR, et al. (1978) Concurrent diagnostic validity of a structured psychiatric interview. Archives of General Psychiatry35: 849–853.
47.
HirdesJPVan EverdingenCFerrisJ, et al. (2020) The interRAI suite of mental health assessment instruments: An integrated system for the continuum of care. Frontiers in Psychiatry10: 926–926.
48.
HjorthøjCRHjorthøjARNordentoftM (2012) Validity of timeline follow-back for self-reported use of cannabis and other illicit substances – Systematic review and meta-analysis. Addictive Behaviors37: 225–233.
49.
HoolahanBKellyBStainHJ, et al. (2006) Co-morbid drug and alcohol and mental health issues in a rural New South Wales Area Health Service. The Australian Journal of Rural Health14: 148–153.
50.
HumeniukREHenry-EdwardsSAliRL, et al. (2010) The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Manual for Use in Primary Care. Geneva: World Health Organization.
51.
HuntGELargeMMClearyM, et al. (2018) Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug and Alcohol Dependence191: 234–258.
52.
HuntGEMalhiGSClearyM, et al. (2016) Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990–2015: Systematic review and meta-analysis. Journal of Affective Disorders206: 331–349.
53.
HuntGEMalhiGSLaiHMX, et al. (2020) Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990–2019: Systematic review and meta-analysis. Journal of Affective Disorders266: 288–304.
54.
InchaustiLGorostizaIGonzalez TorresMA, et al. (2023) The transition to schizophrenia spectrum disorder from a first psychotic episode that did or did not appear to be induced by substance use. Psychiatry Research328: 1–6.
55.
JingwaJ (2024) Implementation of an Alcohol Screening Tool and a Treatment Referral Protocol by Providers at an Adult Outpatient Mental Health Clinic. Ann Arbor, MI: ProQuest Information & Learning.
56.
KarlssonAHåkanssonA (2018) Gambling disorder, increased mortality, suicidality, and associated comorbidity: A longitudinal nationwide register study. Journal of Behavioral Addictions7: 1091–1099.
57.
KarterudSArefjordNAndresenNE, et al. (2009) Substance use disorders among personality disordered patients admitted for day hospital treatment. Implications for service developments. Nordic Journal of Psychiatry63: 57–63.
58.
KavanaghDJTrembathMShockleyN, et al. (2011) The DrugCheck problem list: A new screen for substance use disorders in people with psychosis. Addictive Behaviors36: 927–932.
59.
KesserwaniJKadraGDownsJ, et al. (2019) Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine. Journal of Psychopharmacology33: 449–458.
60.
KrollDSSmallwoodJChangG (2013) Drug screens for psychiatric patients in the emergency department: Evaluation and recommendations. Psychosomatics54: 60–66.
61.
KwakoLEMomenanRLittenRZ, et al. (2016) Addictions neuroclinical assessment: A neuroscience-based framework for addictive disorders. Biological Psychiatry80: 179–189.
62.
LappinJArunogiriSFouldsJ, et al. (2018) It is a drug and alcohol problem, not a mental health problem: Reflections on treatment pathways for co-occurring disorders. Australian and New Zealand Journal of Psychiatry52: 64.
63.
LappinJMSaraGEFarrellM (2017) Methamphetamine-related psychosis: An opportunity for assertive intervention and prevention. Addiction112: 927–928.
64.
LaugharneRDanielsOJLutchmanR (1997) The prevalence of alcohol problems amongst in-patients referred to the liaison psychiatrist. Addiction Research5: 379–382.
65.
LeijtenFRMStruckmannVVan GinnekenE, et al. (2018) The Selfie framework for integrated care for multi-morbidity: Development and description. Health Policy122: 12–22.
66.
MackCSuZWestreichD (2018) AHRQ Methods for Effective Health Care. Managing Missing Data in Patient Registries: Addendum to Registries for Evaluating Patient Outcomes: A User’s Guide, 3 Edition. Rockville, MD: Agency for Healthcare Research and Quality.
67.
MarsdenJEastwoodBAliR, et al. (2014) Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT). Drug and Alcohol Dependence139: 121–131.
68.
MarsdenJFarrellMBradburyC, et al. (2008) Development of the treatment outcomes profile. Addiction103: 1450–1460.
69.
Martín-SantosRFonsecaFDomingo-SalvanyA, et al. (2006) Dual diagnosis in the psychiatric emergency room in Spain. The European Journal of Psychiatry20: 147–156.
70.
MathiasSLubmanDIHidesL (2008) Substance-induced psychosis: A diagnostic conundrum. The Journal of Clinical Psychiatry69: 358–367.
71.
McGovernMPClarkRESamnalievM (2007) Co-occurring psychiatric and substance use disorders: A multistate feasibility study of the quadrant model. Psychiatric Services58: 949–954.
72.
McGovernMPLambert-HarrisCGothamHJ, et al. (2014) Dual diagnosis capability in mental health and addiction treatment services: An assessment of programs across multiple state systems. Administration and Policy in Mental Health41: 205–214.
73.
McGrathJJLimCCWPlana-RipollO, et al. (2020) Comorbidity within mental disorders: A comprehensive analysis based on 145 990 survey respondents from 27 countries. Epidemiology and Psychiatric Sciences29: e153.
74.
McKetinRLeungJStockingsE, et al. (2019) Mental health outcomes associated with of the use of amphetamines: A systematic review and meta-analysis. eClinicalMedicine16: 81–97.
75.
McLellanATLuborskyLWoodyGE, et al. (1980) An improved diagnostic evaluation instrument for substance abuse patients: The addiction severity index. The Journal of Nervous and Mental Disease168: 26–33.
76.
MenezesPRJohnsonSThornicroftG, et al. (1996) Drug and alcohol problems among individuals with severe mental illness in south London. The British Journal of Psychiatry168: 612–619.
77.
MinkoffK (1989) An integrated treatment model for dual diagnosis of psychosis and addiction. Hospital & Community Psychiatry40: 1031–1036.
78.
MinkoffK (2001) Developing standards of care for individuals with co-occurring psychiatric and substance use disorders. Psychiatric Services52: 597–599.
79.
MinkoffKCovellN (2019) Integrated Systems and Services for People with Co-Occurring Mental Health and Substance Use Conditions: What’s Known, What’s New, and What’s Now? (ed. SAAMHSA Center For Mental Health Services). Alexandria, VA: National Association of State Mental Health Program Directors.
80.
MomenNCPlana-RipollOAgerboE, et al. (2020) Association between mental disorders and subsequent medical conditions. New England Journal of Medicine382: 1721–1731.
81.
MorganVAWaterreusAJablenskyA, et al. (2012) People living with psychotic illness in 2010: The second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry46: 735–752.
82.
MueserKTYarnoldPRLevinsonDF, et al. (1990) Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophrenia Bulletin16: 31–56.
83.
MurrieBLappinJLargeM, et al. (2020) Transition of substance-induced, brief, and atypical psychoses to schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin46: 505–516.
84.
NehlinCArinellHDyster-AasJ, et al. (2017) Alcohol habits and health care use in patients with psychiatric disorders. Journal of Dual Diagnosis13: 247–253.
85.
NICE (2011) Coexisting Severe Mental Illness (Psychosis) and Substance Misuse: Assessment and Management in Healthcare Settings (ed. NHS). Manchester: National Institute for Health and Care Excellence (NICE).
86.
OgrincGDaviesLGoodmanD, et al. (2016) SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Quality & Safety25: 986–992.
87.
PageMJMckenzieJEBossuytPM, et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ372: n71.
88.
ParkerCMcNeillARatschenE (2012) Tailored tobacco dependence support for mental health patients: A model for inpatient and community services. Addiction107: 18–25.
89.
ParranTBondesonMMccormickR, et al. (2018) Assessment. In: MillerS (ed.) The ASAM Principles of Addiction Medicine, 6th Edition.Philadelphia, PA: Wolters Kluwer, pp. 359–367.
90.
PetersenIWelchCANazarethI, et al. (2019a) Health indicator recording in UK primary care electronic health records: Key implications for handling missing data. Clinical Epidemiology11: 157–167.
91.
PetersenSMToftdahlNGNordentoftM, et al. (2019b) Schizophrenia is associated with increased risk of subsequent substance abuse diagnosis: A nation-wide population-based register study. Addiction114: 2217–2226.
92.
Plana-RipollOPedersenCBHoltzY, et al. (2019) Exploring comorbidity within mental disorders among a Danish national population. JAMA Psychiatry76: 259–270.
93.
PleverSKiselySBonevskiB, et al. (2023) Can improvement in delivery of smoking cessation care be sustained in psychiatry inpatient settings through a system change intervention? An analysis of statewide administrative health data. Australian and New Zealand Journal of Psychiatry57: 1375–1383.
94.
PleverSMcCarthyIAnzolinM, et al. (2020) Queensland smoking care in adult acute mental health inpatient units: Supporting practice change. Australian and New Zealand Journal of Psychiatry54: 919–927.
RadiganMLiHMillerGA, et al. (2016) Sustaining screening of key health risk factors in New York State Mental Health clinics after implementation of the health indicator initiative. Psychiatric Services67: 425–430.
97.
RANZCP (2015) Keeping Body and Mind Together: Improving the Physical Health and Life Expectancy of People With Serious Mental Illness. Melbourne, VIC, Australia: The Royal Australian and New Zealand College of Psychiatrists.
98.
RebgetzSConusPHidesL, et al. (2014) Predictors of substance use reduction in an epidemiological first-episode psychosis cohort. Early Intervention in Psychiatry8: 358–365.
99.
ReillyJMcDermottBDillonJ (2019) Standardized drug and alcohol questions at admission to an acute adult mental health unit: Clarifying the burden of dual diagnoses across a five-year period. Australasian Psychiatry27: 270–274.
100.
ReillyJMeurkCHeffernanE, et al. (2023) Substance use disorder screening and brief intervention in routine clinical practice in specialist adult mental health services: A systematic review. Australian and New Zealand Journal of Psychiatry57: 793–810.
101.
ReillyJMeurkCHeffernanEB (2020) What Approaches are Used to Identify and Treat Individuals With Substance Use Disorders in Adult Specialist Mental Health Services, and How Effective are They?Chichester: PROSPERO.
102.
ResarRGriffinFHaradenC, et al. (2012) Using Care Bundles to Improve Health Care Quality (IHI Innovation Series White Paper). Cambridge, MA: Institute for Healthcare Improvement.
103.
RichardsJEShortreedSMSimonGE, et al. (2020) Short-term risk of suicide attempt associated with patterns of patient-reported alcohol use determined by routine Audit-C among adults receiving mental healthcare. General Hospital Psychiatry62: 79–86.
104.
RichardsJESimonGEBoggsJM, et al. (2021) An implementation evaluation of ‘Zero Suicide’ using normalization process theory to support high-quality care for patients at risk of suicide. Implementation Research and Practice2: 26334895211011769.
105.
RichardsonJDKetchesonFKingL, et al. (2017) Psychiatric Comorbidity Pattern in Treatment-Seeking Veterans. Amsterdam: Elsevier Science.
106.
RiesRKDemirsoyARussoJE, et al. (2001) Reliability and clinical utility of DSM-IV substance-induced psychiatric disorders in acute psychiatric inpatients. The American Journal on Addictions10: 308–318.
107.
RiesRKYuodelis-FloresCRoy-ByrnePP, et al. (2009) Addiction and suicidal behavior in acute psychiatric inpatients. Comprehensive Psychiatry50: 93–99.
108.
RobinsLNHelzerJECroughanJ, et al. (1981) National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Archives of General Psychiatry38: 381–389.
109.
RobinsLNHelzerJERatcliffKS, et al. (1982) Validity of the diagnostic interview schedule, version II: DSM-III diagnoses. Psychological Medicine12: 855–870.
110.
RumpfHJBohlmannJHillA, et al. (2001) Physicians’ low detection rates of alcohol dependence or abuse: A matter of methodological shortcomings?General Hospital Psychiatry23: 133–137.
111.
RushB (2021) Screening and assessment for people with substance use disorders: A focus on developed countries. In: El-GuebalyNCarràGGalanterM, et al. (eds) Textbook of Addiction Treatment: International Perspectives. Cham: Springer, pp. 673–688.
112.
RushBUrbanoskiK (2019) Seven core principles of substance use treatment system design to aid in identifying strengths, gaps, and required enhancements. Journal of Studies on Alcohol and Drugs, Supplement18: 9–21.
113.
RyanAHolmesJHuntV, et al. (2014) Validation and implementation of the Australian Treatment Outcomes Profile in specialist drug and alcohol settings. Drug and Alcohol Review33: 33–42.
114.
SahaSLimCCDegenhardtL, et al. (2021) Comorbidity between mood and substance-related disorders: A systematic review and meta-analysis. Australian and New Zealand Journal of Psychiatry56: 757–770.
115.
SalisburyC (2012) Multimorbidity: Redesigning health care for people who use it. The Lancet380: 7–9.
116.
SametSWaxmanRHatzenbuehlerM, et al. (2007) Assessing addiction: Concepts and instruments. Addiction Science & Clinical Practice4: 19–31.
117.
SAMHSA (2019) Enhancing Motivation for Change in Substance Use Disorder Treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA).
118.
SAMHSA (2020) Substance Use Disorder Treatment for People With Co-Occurring Disorders. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA).
119.
SaundersJB (2017) Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11. Current Opinion in Psychiatry30: 227–237.
120.
SaundersJBAaslandOGBaborTF, et al. (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): Who collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction88: 791–804.
121.
SaundersJBConnorJStjepanovicD (2021) Screening and assessment. In: HaberPSRiordanBC (eds) Guidelines for the Treatment of Alcohol Problems. Sydney, NSW, Australia: Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney, pp. 37–68.
122.
SaundersJBDegenhardtLReedGM, et al. (2019) Alcohol use disorders in ICD-11: Past, present, and future. Alcoholism, Clinical and Experimental Research43: 1617–1631.
123.
SchuckitMA (2006) Comorbidity between substance use disorders and psychiatric conditions. Addiction101: 76–88.
124.
SearbyAMaudePMcGrathI (2016) Prevalence of co-occurring alcohol and other drug use in an Australian older adult mental health service. International Journal of Mental Health Nursing25: 151–158.
125.
SepehrmaneshZAhmadvandAMoravejiA (2014) Comorbidity and pattern of substance use in hospitalized psychiatric patients. Iranian Red Crescent Medical Journal16: e19282.
126.
SinghJPGrannMFazelS (2011) A comparative study of violence risk assessment tools: A systematic review and metaregression analysis of 68 studies involving 25,980 participants. Clinical Psychology Review31: 499–513.
127.
SocíasMEVolkowNWoodE (2016) Adopting the ‘cascade of care’ framework: An opportunity to close the implementation gap in addiction care?Addiction111: 2079–2081.
128.
State of Victoria (2021) Final Report, Summary and Recommendations. Melbourne, VIC, Australia: Royal Commission into Victoria’s Mental Health System.
129.
SterneJACSavovićJPageMJ (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. British Medical Journal366: I4898.
130.
SoxHCLewisRJ (2016) Pragmatic Trials Practical Answers to “Real World” Questions. JAMA316: 1205–06.
131.
SweetmanJRaistrickDMdegeND, et al. (2013) A systematic review of substance misuse assessment packages. Drug and Alcohol Review32: 347–355.
132.
ThunganaYZingelaZVan WykS (2019) First-episode psychosis and substance use in Nelson Mandela Bay: Findings from an acute mental health unit. The South African Journal of Psychiatry25: 1372–1376.
133.
Turning Point (2021) AOD Comprehensive Assessment. Melbourne, VIC, Australia: Department of Health, Victoria.
134.
US Department of HHS Office of the Surgeon General (2016) Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington, DC: US Department of HHS Office of the Surgeon General.
135.
VickNKippingC (2009) National review of NHS acute inpatient mental health services in England: Implications for working with people with a dual diagnosis. Advances in Dual Diagnosis2: 4–12.
136.
VignaultCMasséAGouronD, et al. (2021) The potential impact of recreational cannabis legalization on the prevalence of cannabis use disorder and psychotic disorders: A retrospective observational study. Canadian Journal of Psychiatry66: 1069–1076.
137.
WeaverTHickmanMRutterD, et al. (2001) The prevalence and management of co-morbid substance misuse and mental illness: Results of a screening survey in substance misuse and mental health treatment populations. Drug and Alcohol Review20: 407–416.
138.
WhitingDGulatiGGeddesJR, et al. (2022) Association of schizophrenia spectrum disorders and violence perpetration in adults and adolescents from 15 Countries: A systematic review and meta-analysis. JAMA Psychiatry79: 120–132.
139.
WhitingDLichtensteinPFazelS (2021) Violence and mental disorders: A structured review of associations by individual diagnoses, risk factors, and risk assessment. The Lancet Psychiatry8: 150–161.
140.
WHO (2019) International Classification of Diseases and Related Health Problems 11th Revision. Geneva: World Health Organization.
141.
WHO (2022) International Classification of Diseases Eleventh Revision (ICD-11). GenevaWorld Health Organization.
142.
WilliamsARNunesEVBisagaA, et al. (2018) Developing an opioid use disorder treatment cascade: A review of quality measures. Journal of Substance Abuse Treatment91: 57–68.
143.
WhitingPFRutjesAWWestwoodME, et al. (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine155: 529–536.
144.
WingJKBeevorASCurtisRH, et al. (1998) Health of the Nation Outcome Scales (HONOS). Research and development. The British Journal of Psychiatry172: 11–18.
145.
WuLTPayneEHRosemanK, et al. (2019) Clinical workflow and substance use screening, brief intervention, and referral to treatment data in the electronic health records: A national drug abuse treatment clinical trials network study. EGEMS7: 35.
146.
WüsthoffLEWaalHRuudT, et al. (2011a) A cross-sectional study of patients with and without substance use disorders in Community Mental Health Centres. BMC Psychiatry11: 93.
147.
WüsthoffLEWaalHRuudT, et al. (2011b) Identifying co-occurring substance use disorders in community mental health centres Tailored approaches are needed. Nordic Journal of Psychiatry65: 58–64.
148.
WylieKHouseAStorerD, et al. (1996) Deliberate self-harm and substance dependence: The management of patients seen in the general hospital. Journal of Mental Health Administration23: 246–252.
149.
YuanCTMcGintyEEDalcinA, et al. (2022) Scaling evidence-based interventions to improve the cardiovascular health of people with serious mental illness. Frontiers in Psychiatry13: 793146.
150.
ZolezziMAl-RawiSEltorkiY (2022) An exploration of smoking patterns among people with serious mental illness attending an outpatient clinic in Qatar. Neuropsychiatric Disease and Treatment18: 2847–2854.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
